Global Genetic Testing Market, 2026-2035
Description
Global Genetic Testing Market Size, Share & Trends Analysis Report by technology (Polymerase Chain Reaction, DNA sequencing, Cytogenetics (Karyotyping and FISH), Microarrays, Gene Expression Profiling) By Type (Prenatal and New-Born Genetic Testing, Predictive Testing, Diagnostic Testing, Carrier Testing, and Other) By Diseases (Cancer, Alzheimer’s and Parkinson, Fanconi Anaemia, Sickle Cell Anaemia, Cardiovascular Diseases, and Others), Forecast Period (2026-2035)
Industry Overview
Genetic testing market was valued at $22.1 billion in 2025 and is projected to reach $44.0 billion by 2035, growing at a CAGR of 6.1% during the forecast period (2026-2035). The global genetic testing market is experiencing steady growth, driven by increasing awareness of early disease detection and personalized medicine. Advances in technologies such as polymerase chain reaction, DNA sequencing, and microarray analysis have significantly improved accuracy and efficiency in genetic diagnostics. The rising prevalence of chronic and hereditary diseases, including cancer and cardiovascular disorders, has further increased demand for genetic testing services. Expanding applications in prenatal, newborn, predictive, and diagnostic testing are strengthening market adoption across healthcare systems. Supportive government initiatives and growing investments in genomics research are also contributing to market expansion. Additionally, continuous innovation and declining costs of genetic testing technologies are expected to sustain long-term market growth during the forecast period.
Market Dynamics
Advancement in Genetic Testing Technologies
Continuous innovation in polymerase chain reaction, next-generation DNA sequencing, and gene expression profiling is transforming the genetic testing landscape. These technologies are delivering higher accuracy, faster turnaround times, and improved scalability for large-scale testing. The integration of automation and bioinformatics tools is further enhancing data interpretation and clinical utility. As a result, laboratories and healthcare providers are increasingly adopting advanced platforms to improve diagnostic outcomes. Technological progress is also contributing to cost efficiency, making genetic testing more accessible. This trend is expected to remain a key driver of market expansion over the forecast period.
Rising Demand for Predictive and Preventive Healthcare
Growing emphasis on early diagnosis and preventive care is significantly influencing the genetic testing market. Predictive and carrier testing are gaining traction as individuals seek to assess genetic risks associated with cancer, cardiovascular diseases, and neurological disorders. Increased awareness of inherited conditions and the benefits of early intervention is supporting wider adoption. Healthcare systems are also encouraging preventive testing to reduce long-term treatment costs. This shift toward proactive healthcare management is strengthening demand across both developed and emerging markets. Consequently, predictive genetic testing is becoming an integral component of modern healthcare strategies.
Market Segmentation
DNA sequencing represents the largest and fastest-growing technology sub-segment within the genetic testing market due to its broad clinical and research applicability. Continuous improvements in sequencing speed, accuracy, and cost efficiency are enabling large-scale genomic analysis across healthcare settings. Market growth is further supported by rising demand for comprehensive genetic insights in rare disease identification and inherited disorder screening. Leading companies such as Illumina, Thermo Fisher Scientific, and BGI Genomics are strengthening their portfolios through platform upgrades and strategic collaborations. Recent developments indicate increased use of high-throughput and whole-genome sequencing solutions. This sub-segment is expected to retain strong momentum throughout the forecast period.
Rising Focus on Cardiovascular Disease Genetic Testing
Genetic testing for cardiovascular diseases is emerging as a high-growth, disease-based sub-segment, supported by the increasing prevalence of inherited cardiac conditions worldwide. In the United States, heart disease remains the leading cause of health-related loss across most demographic groups, highlighting the scale of unmet clinical need. National health data indicate that cardiovascular conditions accounted for approximately 919,032 cases in 2023, representing nearly one-third of all recorded outcomes. Early identification of genetic predisposition is improving risk stratification and long-term clinical management pathways. Advances in molecular diagnostics have strengthened the accuracy and reliability of inherited cardiac disorder detection. Companies such as Thermo Fisher Scientific, Invitae, and QIAGEN are expanding cardiovascular-focused testing panels, with growing adoption observed in preventive cardiology and family screening initiatives.
Regional Outlook
The global genetic testing market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Leadership Driven by Innovation and Clinical Adoption
The North American genetic testing market maintains a leading position due to advanced healthcare infrastructure and strong integration of genomic technologies into clinical practice. High adoption of next-generation sequencing and polymerase chain reaction–based testing supports early diagnosis and precision healthcare initiatives. Key companies such as Illumina, Thermo Fisher Scientific, and Myriad Genetics continue to strengthen their market presence through product innovation and strategic collaborations. Supportive reimbursement frameworks and established regulatory systems in the US and Canada encourage widespread utilization. Recent trends include growing use of genetic testing in preventive healthcare and risk assessment programs. Ongoing investment in research and development is reinforcing long-term market stability. These factors collectively support sustained regional market growth.
Asia-Pacific Emerging Growth Supported by Expanding Healthcare Access
The Asia-Pacific genetic testing market is witnessing rapid expansion, supported by rising healthcare investments and increasing awareness of genetic conditions. Large populations in China, India, and Southeast Asia are driving demand for diagnostic and carrier testing services. Companies such as Roche, QIAGEN, and regional players are expanding operations through partnerships and localized product offerings. Recent trends reflect increased adoption of cost-efficient testing platforms and government-backed genomic initiatives. Improvements in laboratory infrastructure and private healthcare participation are strengthening service availability. Regulatory advancements are also facilitating faster market entry for new technologies. As a result, the region is positioned for accelerated growth over the forecast period.
Market Players Outlook
The major companies operating in the global genetic testing market include Danaher Corporation (Cepheid Inc.), Exact Sciences Corp., Illumina, Inc., Invitae Corp., and Qiagen N.V., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
Industry Overview
Genetic testing market was valued at $22.1 billion in 2025 and is projected to reach $44.0 billion by 2035, growing at a CAGR of 6.1% during the forecast period (2026-2035). The global genetic testing market is experiencing steady growth, driven by increasing awareness of early disease detection and personalized medicine. Advances in technologies such as polymerase chain reaction, DNA sequencing, and microarray analysis have significantly improved accuracy and efficiency in genetic diagnostics. The rising prevalence of chronic and hereditary diseases, including cancer and cardiovascular disorders, has further increased demand for genetic testing services. Expanding applications in prenatal, newborn, predictive, and diagnostic testing are strengthening market adoption across healthcare systems. Supportive government initiatives and growing investments in genomics research are also contributing to market expansion. Additionally, continuous innovation and declining costs of genetic testing technologies are expected to sustain long-term market growth during the forecast period.
Market Dynamics
Advancement in Genetic Testing Technologies
Continuous innovation in polymerase chain reaction, next-generation DNA sequencing, and gene expression profiling is transforming the genetic testing landscape. These technologies are delivering higher accuracy, faster turnaround times, and improved scalability for large-scale testing. The integration of automation and bioinformatics tools is further enhancing data interpretation and clinical utility. As a result, laboratories and healthcare providers are increasingly adopting advanced platforms to improve diagnostic outcomes. Technological progress is also contributing to cost efficiency, making genetic testing more accessible. This trend is expected to remain a key driver of market expansion over the forecast period.
Rising Demand for Predictive and Preventive Healthcare
Growing emphasis on early diagnosis and preventive care is significantly influencing the genetic testing market. Predictive and carrier testing are gaining traction as individuals seek to assess genetic risks associated with cancer, cardiovascular diseases, and neurological disorders. Increased awareness of inherited conditions and the benefits of early intervention is supporting wider adoption. Healthcare systems are also encouraging preventive testing to reduce long-term treatment costs. This shift toward proactive healthcare management is strengthening demand across both developed and emerging markets. Consequently, predictive genetic testing is becoming an integral component of modern healthcare strategies.
Market Segmentation
- Based on the technology, the market is segmented into polymerase chain reaction, DNA sequencing, cytogenetics, microarrays, and gene expression profiling.
- Based on the type, the market is segmented into prenatal and newborn genetic testing, predictive testing, diagnostic testing, carrier testing, and other.
- Based on the disease, the market is segmented into cancer, alzheimer’s and parkinson's, sickle cell anaemia, Fanconi anaemia, cardiovascular disease, and others.
DNA sequencing represents the largest and fastest-growing technology sub-segment within the genetic testing market due to its broad clinical and research applicability. Continuous improvements in sequencing speed, accuracy, and cost efficiency are enabling large-scale genomic analysis across healthcare settings. Market growth is further supported by rising demand for comprehensive genetic insights in rare disease identification and inherited disorder screening. Leading companies such as Illumina, Thermo Fisher Scientific, and BGI Genomics are strengthening their portfolios through platform upgrades and strategic collaborations. Recent developments indicate increased use of high-throughput and whole-genome sequencing solutions. This sub-segment is expected to retain strong momentum throughout the forecast period.
Rising Focus on Cardiovascular Disease Genetic Testing
Genetic testing for cardiovascular diseases is emerging as a high-growth, disease-based sub-segment, supported by the increasing prevalence of inherited cardiac conditions worldwide. In the United States, heart disease remains the leading cause of health-related loss across most demographic groups, highlighting the scale of unmet clinical need. National health data indicate that cardiovascular conditions accounted for approximately 919,032 cases in 2023, representing nearly one-third of all recorded outcomes. Early identification of genetic predisposition is improving risk stratification and long-term clinical management pathways. Advances in molecular diagnostics have strengthened the accuracy and reliability of inherited cardiac disorder detection. Companies such as Thermo Fisher Scientific, Invitae, and QIAGEN are expanding cardiovascular-focused testing panels, with growing adoption observed in preventive cardiology and family screening initiatives.
Regional Outlook
The global genetic testing market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Leadership Driven by Innovation and Clinical Adoption
The North American genetic testing market maintains a leading position due to advanced healthcare infrastructure and strong integration of genomic technologies into clinical practice. High adoption of next-generation sequencing and polymerase chain reaction–based testing supports early diagnosis and precision healthcare initiatives. Key companies such as Illumina, Thermo Fisher Scientific, and Myriad Genetics continue to strengthen their market presence through product innovation and strategic collaborations. Supportive reimbursement frameworks and established regulatory systems in the US and Canada encourage widespread utilization. Recent trends include growing use of genetic testing in preventive healthcare and risk assessment programs. Ongoing investment in research and development is reinforcing long-term market stability. These factors collectively support sustained regional market growth.
Asia-Pacific Emerging Growth Supported by Expanding Healthcare Access
The Asia-Pacific genetic testing market is witnessing rapid expansion, supported by rising healthcare investments and increasing awareness of genetic conditions. Large populations in China, India, and Southeast Asia are driving demand for diagnostic and carrier testing services. Companies such as Roche, QIAGEN, and regional players are expanding operations through partnerships and localized product offerings. Recent trends reflect increased adoption of cost-efficient testing platforms and government-backed genomic initiatives. Improvements in laboratory infrastructure and private healthcare participation are strengthening service availability. Regulatory advancements are also facilitating faster market entry for new technologies. As a result, the region is positioned for accelerated growth over the forecast period.
Market Players Outlook
The major companies operating in the global genetic testing market include Danaher Corporation (Cepheid Inc.), Exact Sciences Corp., Illumina, Inc., Invitae Corp., and Qiagen N.V., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In October 2025, A.D.A.M. Innovations and SOPHiA GENETICS entered a strategic agreement to introduce advanced liquid biopsy genomic testing to Japan, announced at ESMO. The partnership will launch MSK-ACCESS powered by SOPHiA DDMTM, an AI-driven liquid biopsy test that detects actionable cancer-related genomic alterations from a single blood sample. The collaboration also aims to commercialize a companion diagnostic to advance personalized and precision cancer care in Japan.
- In April 2025, QIAGEN N.V. announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling. These updates include a new set of QIAseq panels for comprehensive genomic profiling (CGP) and a new QIAcuity digital PCR (dPCR) kit and assays for cell and gene therapy quality control, along with a new free, limited version of the Human Somatic Mutation Database (HSMD) from the QIAGEN Digital Insights (QDI) bioinformatics business.
- In July 2023, Quest Diagnostics announced the launch of its first consumer-initiated genetic test, available through the company's consumer health business at questhealth.com. Called Genetic Insights, the new offering helps individuals understand their potential risk of developing certain inheritable health conditions, with advanced technology and end-to-end support that includes personalized health reports and access to genetic counseling.
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global genetic testing market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
250 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Genetic Testing Market Sales Analysis – Technology Type Disease ($ Million)
- Genetic Testing Market Sales Performance of Top Countries
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Genetic Testing Market Trends
- 2.2.2. Market Recommendations
- 2.3. Porter's Five Forces Analysis for the Genetic Testing Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For Global Genetic Testing Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Genetic Testing Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For Global Genetic Testing Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard – Genetic Testing Market Revenue and Share by Manufacturers
- Genetic Testing Product Comparison Analysis
- Top Market Player Ranking Matrix
- 4.2. Key Company Analysis
- 4.2.1. Danaher Corp. (Cepheid Inc.)
- 4.2.1.1. Overview
- 4.2.1.2. Product Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. Exact Sciences Corp.
- 4.2.2.1. Overview
- 4.2.2.2. Product Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. Illumina, Inc.
- 4.2.3.1. Overview
- 4.2.3.2. Product Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Myriad Genetics, Inc.
- 4.2.4.1. Overview
- 4.2.4.2. Product Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. Qiagen N.V
- 4.2.5.1. Overview
- 4.2.5.2. Product Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration
- 5. Global Genetic Testing Market Sales Analysis by Technology ($ Million)
- 5.1. Polymerase Chain Reaction
- 5.2. DNA Sequencing
- 5.3. Cytogenetics (Karyotyping and FISH)
- 5.4. Microarrays
- 5.5. Gene Expression Profiling
- 6. Global Genetic Testing Market Sales Analysis by Type ($ Million)
- 6.1. Prenatal and New-Born Genetic Testing
- 6.2. Predictive Testing
- 6.3. Diagnostic Testing
- 6.4. Carrier Testing
- 6.5. Other
- 7. Global Genetic Testing Market Sales Analysis by Disease ($ Million)
- 7.1. Cancer
- 7.2. Alzheimer’s and Parkinson's
- 7.3. Sickle Cell Anaemia
- 7.4. Fanconi Anaemia
- 7.5. Cardiovascular Disease
- 7.6. Others
- 8. Regional Analysis
- 8.1. North American Genetic Testing Market Sales Analysis – Technology Type Disease Country ($ Million)
- Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
- 8.2. European Genetic Testing Market Sales Analysis – Technology Type Disease Country ($ Million)
- Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
- 8.3. Asia-Pacific Genetic Testing Market Sales Analysis – Technology Type Disease Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
- 8.4. Rest of the World Genetic Testing Market Sales Analysis – Technology Type Disease Country ($ Million)
- Macroeconomic Factors for Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa
- 9. Company Profiles
- 9.1. Abbott Corp.
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
- 9.2. AlphaBiolabs Ltd.
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
- 9.3. Asuragen, Inc.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
- 9.4. BGI Genomics Co., Ltd.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
- 9.5. Bio-Rad Laboratories Inc.
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
- 9.6. Blueprint Genetics Oy
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
- 9.7. Exact Sciences Corp.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
- 9.8. F. Hoffmann-La Roche AG (Roche)
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
- 9.9. Fulgent Genetics, Inc.
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
- 9.10. GeneTech Pvt. Ltd.
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
- 9.11. Laboratory Corp
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
- 9.12. Medicover Genetics GmbH
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
- 9.13. Myriad Genetics, Inc
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
- 9.14. Natera, Inc.
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
- 9.15. Navigene Pvt. Ltd.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
- 9.16. Nebula Genomics
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
- 9.17. Qiagen N.V.
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
- 9.18. TellmeGen Ltd.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
- 9.19. Thermo Fisher Scientific Inc.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
- 9.20. Illumina, Inc.
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
